age1, a San Francisco, CA-based venture capital firm catalyzing the next generation of founder-led longevity biotech companies, launched officially.
The firm, which held an initial closing for $35m, aims to build a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related disease.
Built on the foundation of The Longevity Fund, and co-founded by Laura Deming, founder of The Longevity Fund, and Alex Colville, Ph.D. who studied the biology of aging at Stanford and previous biotech investment manager at prestigious family offices, age1 focuses on founders and companies at the earliest stages of first-money in, pre-seed, and seed funding and is capitalized to continue to support companies through later rounds. The firm’s portfolio companies have access to strategic and regulatory guidance from successful founders, the longevity field’s leading experts, and access to a talent network.
age1’s executive team has funded leading companies including Loyal, Gordian Biotechnology, Fauna Bio, Spring Discovery, Arda Therapeutics, Rubedo Life Sciences, Conception, and Bexorg.
Dr. Colville previously established the biotech investment arm of Starbloom Capital and the philanthropic work of the Amaranth Foundation to advance the field of the biology of aging where he managed more than $100m in investments and philanthropy. He will lead age1 as the firm’s General Partner.
Commenting on the announcement, Dr. Colville said: “What started out as Laura’s recognition of a huge gap in the biotech industry of a lack of funding supporting longevity biotech has grown into an unprecedented growth in the amount of longevity biotech companies that promises to change the way people age. The Longevity Fund put longevity biotech on the map. We feel strongly that a next-generation fund with more founder resources is required to accelerate the longevity paradigm shift we are on the precipice of. age1 will back ambitious and pragmatic founders building companies to give people the agency to choose how long they live, in good health.“
Laura Deming added: “age1 is the next chapter in The Longevity Fund’s mission and the inflection point for the field. We’re motivated by the idea that age1 will be the group to make the seemingly impossible possible–extending healthy lifespan.“